JP2015512420A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015512420A5 JP2015512420A5 JP2015503653A JP2015503653A JP2015512420A5 JP 2015512420 A5 JP2015512420 A5 JP 2015512420A5 JP 2015503653 A JP2015503653 A JP 2015503653A JP 2015503653 A JP2015503653 A JP 2015503653A JP 2015512420 A5 JP2015512420 A5 JP 2015512420A5
- Authority
- JP
- Japan
- Prior art keywords
- use according
- hyperalgesia
- drug
- peripheral neuropathy
- peptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims description 22
- 239000003814 drug Substances 0.000 claims description 20
- 229940079593 drug Drugs 0.000 claims description 17
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 17
- 208000004454 Hyperalgesia Diseases 0.000 claims description 15
- 208000035154 Hyperesthesia Diseases 0.000 claims description 15
- 239000002246 antineoplastic agent Substances 0.000 claims description 12
- 229940127089 cytotoxic agent Drugs 0.000 claims description 10
- 208000033808 peripheral neuropathy Diseases 0.000 claims description 9
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 claims description 8
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims description 8
- 229960004528 vincristine Drugs 0.000 claims description 8
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 claims description 8
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 claims description 4
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 claims description 4
- XOGTZOOQQBDUSI-UHFFFAOYSA-M Mesna Chemical compound [Na+].[O-]S(=O)(=O)CCS XOGTZOOQQBDUSI-UHFFFAOYSA-M 0.000 claims description 4
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims description 4
- 229930012538 Paclitaxel Natural products 0.000 claims description 4
- UMILHIMHKXVDGH-UHFFFAOYSA-N Triethylene glycol diglycidyl ether Chemical compound C1OC1COCCOCCOCCOCC1CO1 UMILHIMHKXVDGH-UHFFFAOYSA-N 0.000 claims description 4
- 229960000473 altretamine Drugs 0.000 claims description 4
- 229960004562 carboplatin Drugs 0.000 claims description 4
- 190000008236 carboplatin Chemical compound 0.000 claims description 4
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 claims description 4
- 229960004630 chlorambucil Drugs 0.000 claims description 4
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 4
- 229960004316 cisplatin Drugs 0.000 claims description 4
- 229960000684 cytarabine Drugs 0.000 claims description 4
- 229960003901 dacarbazine Drugs 0.000 claims description 4
- 229960003668 docetaxel Drugs 0.000 claims description 4
- 229960005237 etoglucid Drugs 0.000 claims description 4
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims description 4
- 229960005420 etoposide Drugs 0.000 claims description 4
- 229960000390 fludarabine Drugs 0.000 claims description 4
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 claims description 4
- UUVWYPNAQBNQJQ-UHFFFAOYSA-N hexamethylmelamine Chemical compound CN(C)C1=NC(N(C)C)=NC(N(C)C)=N1 UUVWYPNAQBNQJQ-UHFFFAOYSA-N 0.000 claims description 4
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 claims description 4
- 229960001101 ifosfamide Drugs 0.000 claims description 4
- 229960004635 mesna Drugs 0.000 claims description 4
- IAIWVQXQOWNYOU-FPYGCLRLSA-N nitrofural Chemical compound NC(=O)N\N=C\C1=CC=C([N+]([O-])=O)O1 IAIWVQXQOWNYOU-FPYGCLRLSA-N 0.000 claims description 4
- 229960001907 nitrofurazone Drugs 0.000 claims description 4
- 229960001592 paclitaxel Drugs 0.000 claims description 4
- CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical group CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 claims description 4
- 229960000624 procarbazine Drugs 0.000 claims description 4
- FIAFUQMPZJWCLV-UHFFFAOYSA-N suramin Chemical compound OS(=O)(=O)C1=CC(S(O)(=O)=O)=C2C(NC(=O)C3=CC=C(C(=C3)NC(=O)C=3C=C(NC(=O)NC=4C=C(C=CC=4)C(=O)NC=4C(=CC=C(C=4)C(=O)NC=4C5=C(C=C(C=C5C(=CC=4)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O)C)C=CC=3)C)=CC=C(S(O)(=O)=O)C2=C1 FIAFUQMPZJWCLV-UHFFFAOYSA-N 0.000 claims description 4
- 229960005314 suramin Drugs 0.000 claims description 4
- 229960001603 tamoxifen Drugs 0.000 claims description 4
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims 2
- WYWHKKSPHMUBEB-UHFFFAOYSA-N 6-Mercaptoguanine Natural products N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 claims 1
- -1 Musuchin Chemical compound 0.000 claims 1
- 241001495452 Podophyllum Species 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- YJGVMLPVUAXIQN-XVVDYKMHSA-N podophyllotoxin Chemical compound COC1=C(OC)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@H](O)[C@@H]3[C@@H]2C(OC3)=O)=C1 YJGVMLPVUAXIQN-XVVDYKMHSA-N 0.000 claims 1
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 claims 1
- 229960001278 teniposide Drugs 0.000 claims 1
- 229960003087 tioguanine Drugs 0.000 claims 1
- MNRILEROXIRVNJ-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=NC=N[C]21 MNRILEROXIRVNJ-UHFFFAOYSA-N 0.000 claims 1
- 229940044683 chemotherapy drug Drugs 0.000 description 2
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261618428P | 2012-03-30 | 2012-03-30 | |
| US61/618,428 | 2012-03-30 | ||
| PCT/US2013/034647 WO2013149172A1 (en) | 2012-03-30 | 2013-03-29 | Methods and compositions for the prevention and treatment neuropathy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018063574A Division JP2018123143A (ja) | 2012-03-30 | 2018-03-29 | 神経障害を予防および処置するための方法および組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015512420A JP2015512420A (ja) | 2015-04-27 |
| JP2015512420A5 true JP2015512420A5 (enExample) | 2016-05-26 |
| JP6317324B2 JP6317324B2 (ja) | 2018-04-25 |
Family
ID=49261299
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015503653A Active JP6317324B2 (ja) | 2012-03-30 | 2013-03-29 | 神経障害を予防および処置するための方法および組成物 |
| JP2018063574A Pending JP2018123143A (ja) | 2012-03-30 | 2018-03-29 | 神経障害を予防および処置するための方法および組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018063574A Pending JP2018123143A (ja) | 2012-03-30 | 2018-03-29 | 神経障害を予防および処置するための方法および組成物 |
Country Status (8)
| Country | Link |
|---|---|
| US (5) | US9636378B2 (enExample) |
| EP (3) | EP2830644B1 (enExample) |
| JP (2) | JP6317324B2 (enExample) |
| CN (2) | CN104271146A (enExample) |
| AU (2) | AU2013237827B2 (enExample) |
| CA (1) | CA2869080C (enExample) |
| DK (1) | DK2830644T3 (enExample) |
| WO (1) | WO2013149172A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107312066A (zh) * | 2011-12-09 | 2017-11-03 | 康德生物医疗技术公司 | 芳香族阳离子肽及其用途 |
| WO2013149172A1 (en) | 2012-03-30 | 2013-10-03 | Stealth Peptides International, Inc. | Methods and compositions for the prevention and treatment neuropathy |
| AU2017249218B2 (en) | 2016-04-11 | 2020-08-27 | Arcuate Therapeutics, Inc. | Chiral peptides |
| US10961273B2 (en) | 2016-08-16 | 2021-03-30 | Stealth Biotherapeutics Corp. | N-carboxyanhydride-based-scale synthesis of elamipretide |
| WO2018187400A1 (en) | 2017-04-05 | 2018-10-11 | Stealth Biotherapeutics Corp. | Crystalline salt forms of boc-d-arg-dmt-lys-(boc)-phe-nh2 |
| US10676506B2 (en) | 2018-01-26 | 2020-06-09 | Stealth Biotherapeutics Corp. | Crystalline bis- and tris-hydrochloride salt of elamipretide |
| CN112961249B (zh) * | 2021-02-25 | 2023-08-04 | 兰州大学 | 一类基于阿片肽和大麻肽的双功能肽及其制备方法与应用 |
| WO2024253189A1 (ja) * | 2023-06-09 | 2024-12-12 | 国立大学法人 富山大学 | がん化学療法剤に起因する末梢神経障害の予防剤及び／又は改善剤 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5913318A (ja) | 1982-07-13 | 1984-01-24 | 株式会社村田製作所 | 電子部品の製造方法 |
| US5786332A (en) * | 1995-03-06 | 1998-07-28 | Trega Biosciences, Inc. | Cytokine restraining agents and methods of use in pathologies and conditions associated with altered cytokine levels |
| US6376467B1 (en) | 1998-10-09 | 2002-04-23 | The Regents Of The University Of California | Use of inhibitors of protein kinase C epsilon to treat pain |
| CN101440124B (zh) * | 2003-02-04 | 2012-07-18 | 科内尔研究基金会 | 用于防止线粒体通透性改变的方法 |
| SI2656854T1 (sl) * | 2003-02-04 | 2015-09-30 | Cornell Research Foundation, Inc. | Uporabe aromatsko-kationskega peptida |
| CA3024434A1 (en) | 2004-01-23 | 2005-08-11 | Cornell Research Foundation, Inc. | Methods for reducing oxidative damage |
| CA2947343C (en) * | 2005-09-16 | 2019-04-30 | Cornell Research Foundation, Inc. | Methods for reducing cd36 expression |
| PT2252312E (pt) * | 2008-02-07 | 2014-07-17 | Univ Cornell | Métodos de prevenção ou tratamento de resistência a insulina |
| CN107802821A (zh) * | 2008-02-26 | 2018-03-16 | 康奈尔大学 | 用于防止和治疗急性肾损伤的方法 |
| EP3563862B1 (en) * | 2009-03-20 | 2021-05-05 | The General Hospital Corporation d/b/a Massachusetts General Hospital | D-arg-2'6'-dimethyltyrosine-lys-phe-nh2 for use in the prevention of secondary complications of burn injuries |
| CN105031605A (zh) * | 2009-08-12 | 2015-11-11 | 康奈尔大学 | 预防或治疗代谢综合症的方法 |
| SMT202300433T1 (it) * | 2009-08-24 | 2024-01-10 | Stealth Biotherapeutics Inc | Peptide per l'uso nella prevenzione o nel trattamento della degenerazione maculare |
| US20110082084A1 (en) * | 2009-10-05 | 2011-04-07 | Szeto Hazel H | Methods for the prevention or treatment of heart failure |
| CA2786280A1 (en) * | 2009-12-31 | 2011-07-07 | Stealth Peptides International, Inc. | Methods for the prevention or treatment of vessel occlusion injury |
| AU2010339414A1 (en) * | 2009-12-31 | 2012-07-19 | Stealth Peptides International, Inc. | Methods for performing a coronary artery bypass graft procedure |
| EP2848628A1 (en) * | 2010-01-25 | 2015-03-18 | Cornell University | Aromatic-cationic peptides and uses of same |
| CA2790823A1 (en) * | 2010-02-26 | 2011-09-01 | University Of Florida Research Foundation, Inc. | Mitochondrial-targeted antioxidants protect against mechanical ventilation-induced diaphragm dysfunction and skeletal muscle atrophy |
| WO2011116007A1 (en) * | 2010-03-15 | 2011-09-22 | Stealth Peptides International, Inc. | Combination therapies using cyclosporine and aromatic cationic peptides |
| EP3539554A1 (en) * | 2010-07-09 | 2019-09-18 | Stealth Peptides International, Inc. | Methods for the prevention or treatment of no-reflow following ischemia/reperfusion injury |
| US20120083452A1 (en) * | 2010-09-30 | 2012-04-05 | Perricone Nicholas V | Topical Anesthetic Uses of Szeto-Schiller Peptides |
| KR101351432B1 (ko) | 2011-12-27 | 2014-01-15 | 에스케이씨 주식회사 | 초미세 발포 폴리우레탄 탄성체의 제조방법 |
| WO2013149172A1 (en) * | 2012-03-30 | 2013-10-03 | Stealth Peptides International, Inc. | Methods and compositions for the prevention and treatment neuropathy |
-
2013
- 2013-03-29 WO PCT/US2013/034647 patent/WO2013149172A1/en not_active Ceased
- 2013-03-29 EP EP13769696.9A patent/EP2830644B1/en active Active
- 2013-03-29 US US14/388,705 patent/US9636378B2/en active Active
- 2013-03-29 EP EP18169371.4A patent/EP3406257B1/en active Active
- 2013-03-29 JP JP2015503653A patent/JP6317324B2/ja active Active
- 2013-03-29 CA CA2869080A patent/CA2869080C/en active Active
- 2013-03-29 AU AU2013237827A patent/AU2013237827B2/en active Active
- 2013-03-29 DK DK13769696.9T patent/DK2830644T3/en active
- 2013-03-29 CN CN201380023997.6A patent/CN104271146A/zh active Pending
- 2013-03-29 EP EP16192386.7A patent/EP3170506B1/en active Active
- 2013-03-29 CN CN201710226838.6A patent/CN107320712A/zh active Pending
-
2017
- 2017-04-17 US US15/488,697 patent/US10279008B2/en active Active
- 2017-11-21 AU AU2017265013A patent/AU2017265013B9/en active Active
-
2018
- 2018-03-29 JP JP2018063574A patent/JP2018123143A/ja active Pending
-
2019
- 2019-04-22 US US16/390,799 patent/US10646539B2/en active Active
-
2020
- 2020-04-07 US US16/842,040 patent/US20200397850A1/en not_active Abandoned
-
2022
- 2022-03-01 US US17/684,057 patent/US11998585B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015512420A5 (enExample) | ||
| JP2010270124A5 (enExample) | ||
| NZ708506A (en) | Methods of treating bladder cancer | |
| FI3562486T3 (fi) | Kielenalaisen deksmedetomidiinin käyttö agitaation hoidossa | |
| HK1247835A1 (zh) | 甲状旁腺功能减退症的治疗 | |
| EA201491358A1 (ru) | Вводимые перорально кортикостероидные композиции | |
| WO2013123215A3 (en) | Antiviral drugs for treatment of arenavirus infection | |
| BR112015022197A8 (pt) | uso de um composto para fabricação de um medicamento ou composição farmacêutica para o tratamento de cataplexia | |
| JP2013527232A5 (enExample) | ||
| JP2016512506A5 (enExample) | ||
| BR112013022044A2 (pt) | veículo mastigável para absorção na boca | |
| WO2009029622A3 (en) | Antiviral drugs for treatment of arenavirus infection | |
| RU2017116740A (ru) | Комбинации для лечения рассеянного склероза | |
| EA201490254A1 (ru) | Комбинированное лечение гепатита с | |
| JP2013542205A5 (enExample) | ||
| AR096892A1 (es) | Una combinación farmacéutica para el tratamiento del melanoma | |
| JP2011515481A5 (enExample) | ||
| JP2013509441A5 (enExample) | ||
| WO2009120697A4 (en) | Method and compositions for treatment of cancer | |
| MX340985B (es) | Compuestos de n-heteroarilo. | |
| RU2015137455A (ru) | Пероральная антисептическая композиция для лечения мукозита слизистой оболочки полости рта | |
| WO2017182873A3 (en) | Peptide-oligourea foldamer compounds and methods of their use | |
| CO6341514A2 (es) | Método para reducir la variabilidad de la absorción de paracetamol en pacientes con dismotilidad gástrica | |
| JP2018522028A5 (enExample) | ||
| BR112022019914A2 (pt) | Coadministração de mirdametinibe e lifirafenibe para uso no tratamento de cânceres |